Overview

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-03-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
Phase:
PHASE1
Details
Lead Sponsor:
Janssen Research & Development, LLC